Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

Is Hims & Hers the next big player in telehealth? Our experts break down its business model, growth potential, and the risks ...

Hims & Hers Health stock missed on earnings last night. The company grew sales 73% and profits tripled, but Wall Street ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares of Hims & Hers Inc. fell after hours on Monday after the wellness and telehealth platform’s third-quarter forecast ...

The telehealth-consultation platform posted an increase in profit and revenue for the second quarter on growth in subscribers ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Palantir rose after earnings blew past Wall Street estimates, while shares of Vertex Pharmaceuticals and Hims & Hers ...

HIMS accelerates global expansion with tech-integrated care, leveraging ZAVA and semaglutide for personalized health delivery.

Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. Click here to find out why ...

In its updated report, Hims & Hers Health, Inc. (NYSE:HIMS) said revenues increased by 73 percent to $544.8 million from $315 ...